All In Biotech

Drug Trial Radar · NCT03966898

A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

A Phase III Study to Evaluate Efficacy and Safety of SHR6390 in Combination With Letrozole or Anastrozole Versus Placebo in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jun 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 426 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

426

Planned (sponsor's estimate)

Start

Jul 19, 2019

Primary completion

Dec 30, 2022

Study completion Dec 30, 2023

Sponsor

Sponsor type
Industry
First posted
May 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Letrozole or Anastrozole versus placebo in combination with Letrozole or Anastrozole in Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have not received systemic anticancer therapy are eligible for this study.

Conditions

  • Advanced Breast Cancer

Interventions

  • SHR6390 TabletsDrug

    SHR6390 Tablets

  • Placebo TabletsDrug

    Placebo Tablets

  • Letrozole or Anastrozole TabletsDrug

    Letrozole or Anastrozole Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator-assessed PFSTime frame: Every 8 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, Up to approximately 24 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nayima Bayaxi

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.